TY  - JOUR
AU  - Delgado-Ureña, Mayte
AU  - Ortega, Francisco G
AU  - de Miguel-Pérez, Diego
AU  - Rodriguez-Martínez, Alba
AU  - García-Puche, Jose L
AU  - Ilyine, Hugh
AU  - Lorente, Jose A
AU  - Exposito-Hernandez, Jose
AU  - Garrido-Navas, M Carmen
AU  - Delgado-Ramirez, Miguel
AU  - Serrano, M José
PY  - 2018
DO  - 10.1186/s12967-018-1624-2
UR  - http://hdl.handle.net/10668/12914
T2  - Journal of translational medicine
AB  - The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the...
LA  - en
KW  - Bevacizumab
KW  - Circulating tumor cells
KW  - CyCAR
KW  - Metastatic colorectal cancer
KW  - Prognosis
KW  - RECIST
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cell Line, Tumor
KW  - Colorectal Neoplasms
KW  - Female
KW  - Fluorouracil
KW  - Follow-Up Studies
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Neoplasm Metastasis
KW  - Neoplastic Cells, Circulating
KW  - Organoplatinum Compounds
KW  - Prognosis
KW  - Proportional Hazards Models
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - Reference Standards
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Treatment Outcome
TI  - Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
TY  - research article
VL  - 16
ER  -